AUB ScholarWorks

Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization

Show simple item record

dc.contributor.author Mansour A.M.
dc.contributor.author Mackensen F.
dc.contributor.author Arevalo J.F.
dc.contributor.author Ziemssen F.
dc.contributor.author Mahendradas P.
dc.contributor.author Mehio-Sibai A.
dc.contributor.author Hrisomalos N.
dc.contributor.author Lai T.Y.Y.
dc.contributor.author Dodwell D.
dc.contributor.author Chan W.-M.
dc.contributor.author Ness T.
dc.contributor.author Banker A.S.
dc.contributor.author Pai S.A.
dc.contributor.author Berrocal M.H.
dc.contributor.author Tohme R.
dc.contributor.author Heiligenhaus A.
dc.contributor.author Bashshur Z.F.
dc.contributor.author Khairallah M.
dc.contributor.author Salem K.M.
dc.contributor.author H
dc.contributor.editor
dc.date Sep-2008
dc.date.accessioned 2017-10-05T15:49:18Z
dc.date.available 2017-10-05T15:49:18Z
dc.date.issued 2008
dc.identifier 10.1016/j.ajo.2008.05.024
dc.identifier.isbn
dc.identifier.issn 00029394
dc.identifier.uri http://hdl.handle.net/10938/18771
dc.description.abstract Purpose: To assess the role of bevacizumab in inflammatory ocular neovascularization. Design: Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization. Methods: Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up. Results: At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6-28 or 20-94) to 0.44 (6-17 or 20-55) (P .001). BCVA improved by one to three lines in 34.5percent of the eyes, by four to six lines in 16.7percent of the eyes, and by more than six lines in 14.2percent of the eyes. Function was unchanged in 23.8percent of the eyes. BCVA worsened in 10.7percent (zero to three lines in 7.1percent, more than four lines in 3.6percent). Central foveal thickness decreased from baseline 346 to 252 μm (P .001). For CNV, 32 eyes (43.2percent) had complete regression after the injection, 27 (36.5percent) had partial regression, five (6.8percent) had no response, and 10 eyes (13.5percent) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6percent) had complete regression of new vessels and four eyes (36.4percent) had partial regression after the injection. Conclusions: Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases. © 2008 Elsevier Inc. All rights reserved.
dc.format.extent
dc.format.extent Pages: (410-4160)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: American Journal of Ophthalmology; Publication Year: 2008; Volume: 146; no. 3; Pages: (410-4160);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
dc.type Article
dc.contributor.affiliation Mansour, A.M., Department of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Mackensen, F., Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany
dc.contributor.affiliation Arevalo, J.F., Clinica Oftalmologica Centro Caracas, University of Los Andes, Caracas, Venezuela
dc.contributor.affiliation Ziemssen, F., Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
dc.contributor.affiliation Mahendradas, P., Tuebingen Bevacizumab Study Group, Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India
dc.contributor.affiliation Mehio-Sibai, A., Department of Epidemiology and Population Health, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Hrisomalos, N., Department of Ophthalmology, University of Indiana, Indianapolis, IN, United States
dc.contributor.affiliation Lai, T.Y.Y., Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong
dc.contributor.affiliation Dodwell, D., Springfield Eye Clinic, Springfield, IL, United States
dc.contributor.affiliation Chan, W.-M., Department of Ophthalmology, Chinese University of Hong Kong, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
dc.contributor.affiliation Ness, T., University Eye Hospital, Freiburg, Germany
dc.contributor.affiliation Banker, A.S., Banker's Retina Clinic, Laser Center, Ahmedabad, Gujarat, India
dc.contributor.affiliation Pai, S.A., Tuebingen Bevacizumab Study Group, Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India
dc.contributor.affiliation Berrocal, M.H., Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico
dc.contributor.affiliation Tohme, R., Tuebingen Bevacizumab Study Group, Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India
dc.contributor.affiliation Heiligenhaus, A., Department of Ophthalmology, Uveitis Center, St Franziskus Hospital, Muenster, Germany
dc.contributor.affiliation Bashshur, Z.F., Department of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Khairallah, M., Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
dc.contributor.affiliation Salem, K.M., Department of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Hrisomalos, F.N., Department of Ophthalmology, University of Indiana, Indianapolis, IN, United States
dc.contributor.affiliation Wood, M.H., Eye Surgical Associates, Lincoln, NE, United States
dc.contributor.affiliation Heriot, W., Department of Surgery, Cabrini Medical Center, Malvern, Vic., Australia
dc.contributor.affiliation Adan, A., Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Barcelona, Spain
dc.contributor.affiliation Kumar, A., DR Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
dc.contributor.affiliation Lim, L., Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, Melbourne, Vic., Australia
dc.contributor.affiliation Hall, A., Department of Surgery, Cabrini Medical Center, Malvern, Vic., Australia, Department of Ophthalmology, Alfred Hospital, Melbourne, Vic., Australia
dc.contributor.affiliation Becker, M., Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany
dc.contributor.authorAddress Mansour, A.M.; Department of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon; email: dr.ahmad@cyberia.net.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorDivision
dc.contributor.authorEmail dr.ahmad@cyberia.net.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Mansour, AM
dc.contributor.authorInitials Mackensen, F
dc.contributor.authorInitials Arevalo, JF
dc.contributor.authorInitials Ziemssen, F
dc.contributor.authorInitials Mahendradas, P
dc.contributor.authorInitials Mehio-Sibai, A
dc.contributor.authorInitials Hrisomalos, N
dc.contributor.authorInitials Lai, TYY
dc.contributor.authorInitials Dodwell, D
dc.contributor.authorInitials Chan, WM
dc.contributor.authorInitials Ness, T
dc.contributor.authorInitials Banker, AS
dc.contributor.authorInitials Pai, SA
dc.contributor.authorInitials Berrocal, MH
dc.contributor.authorInitials Tohme, R
dc.contributor.authorInitials Heiligenhaus, A
dc.contributor.authorInitials Bashshur, ZF
dc.contributor.authorInitials Khairallah, M
dc.contributor.authorInitials Salem, KM
dc.contributor.authorInitials Hrisomalos,
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Mansour, AM (reprint author), Amer Univ Beirut, Dept Ophthalmol, POB 113-6044, Beirut, Lebanon.
dc.contributor.authorResearcherID Ziemssen, Focke-B-9564-2009
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Adan A, 2007, GRAEF ARCH CLIN EXP, V245, P1873, DOI 10.1007-s00417-007-0637-y; Benesch M, 2008, ANN ONCOL, V19, P807, DOI 10.1093-annonc-mdm510; Brown J, 1996, OPHTHALMOLOGY, V103, P1100; Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016-j.ajo.2007.02.039; Chung EJ, 2007, GRAEF ARCH CLIN EXP, V245, P1727, DOI 10.1007-s00417-007-0661-y; Fine HF, 2001, AM J OPHTHALMOL, V132, P794, DOI 10.1016-S0002-9394(01)01103-5; FINE SL, 1993, ARCH OPHTHALMOL-CHIC, V111, P19; Flaxel CJ, 1998, EYE, V12, P266; Fujii GY, 2001, AM J OPHTHALMOL, V131, P90, DOI 10.1016-S0002-9394(00)00769-8; Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597; KLEINER RC, 1988, RETINA-J RET VIT DIS, V8, P225; Kumar A, 2007, CAN J OPHTHALMOL, V42, P335, DOI 10.3129-canjophthalmol.i07-026; Macular Photocoagulation Study Group, 1987, ARCH OPHTHALMOL-CHIC, V105, P1499; FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1347; Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097-00006982-200604000-00003; NOWILATY SR, 2006, BR J OPHTHALMOL, V908, P982; OLK RJ, 1984, OPHTHALMOLOGY, V91, P1592; Olsen TW, 1996, OPHTHALMOLOGY, V103, P2061; Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016-j.ajo.2004.03.029; Perentes Y, 2005, OCUL IMMUNOL INFLAMM, V13, P219, DOI 10.1080-09273940490518883; Perentes Y, 2002, KLIN MONATSBL AUGENH, V219, P311, DOI 10.1055-s-2002-30662; Rosenfeld PJ, 2004, OPHTHALMOLOGY, V111, P1725, DOI 10.1016-j.ophtha.2004.02.014; Shah Parag K., 2007, Indian Journal of Ophthalmology, V55, P75; SHAH SS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1533; Travassos A, 2007, OPHTHAL SURG LAS IM, V38, P233; Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007-s00417-003-0734-5
dc.description.citedCount 35
dc.description.citedTotWOSCount 29
dc.description.citedWOSCount 28
dc.format.extentCount 3751
dc.identifier.articleNo
dc.identifier.coden AJOPA
dc.identifier.pubmedID 18619571
dc.identifier.scopusID 49949094774
dc.identifier.url
dc.publisher.address 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Am. J. Ophthalmol.
dc.relation.ispartOfIssue 3
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle American Journal of Ophthalmology
dc.relation.ispartofPubTitleAbbr Am. J. Ophthalmol.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 146
dc.source.ID WOS:000258883900014
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS bevacizumab, 216974-75-3
dc.subject.otherChemCAS Angiogenesis Inhibitors
dc.subject.otherChemCAS Antibodies, Monoclonal
dc.subject.otherChemCAS bevacizumab
dc.subject.otherChemCAS Vascular Endothelial Growth Factor A
dc.subject.otherIndex bevacizumab
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex angiography
dc.subject.otherIndex article
dc.subject.otherIndex clinical trial
dc.subject.otherIndex drug treatment failure
dc.subject.otherIndex female
dc.subject.otherIndex follow up
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex multicenter study
dc.subject.otherIndex ophthalmoscopy
dc.subject.otherIndex optical coherence tomography
dc.subject.otherIndex priority journal
dc.subject.otherIndex remission
dc.subject.otherIndex retina fovea
dc.subject.otherIndex retrospective study
dc.subject.otherIndex subretinal neovascularization
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex visual acuity
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Aged, 80 and over
dc.subject.otherIndex Angiogenesis Inhibitors
dc.subject.otherIndex Antibodies, Monoclonal
dc.subject.otherIndex Child
dc.subject.otherIndex Choroidal Neovascularization
dc.subject.otherIndex Eye Diseases
dc.subject.otherIndex Female
dc.subject.otherIndex Follow-Up Studies
dc.subject.otherIndex Humans
dc.subject.otherIndex Injections
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Optic Disk
dc.subject.otherIndex Retinal Neovascularization
dc.subject.otherIndex Retrospective Studies
dc.subject.otherIndex Tomography, Optical Coherence
dc.subject.otherIndex Vascular Endothelial Growth Factor A
dc.subject.otherIndex Visual Acuity
dc.subject.otherIndex Vitreous Body
dc.subject.otherKeywordPlus SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
dc.subject.otherKeywordPlus PUNCTATE INNER CHOROIDOPATHY
dc.subject.otherKeywordPlus RANDOMIZED CLINICAL-TRIAL
dc.subject.otherKeywordPlus AGGRESSIVE POSTERIOR RETINOPATHY
dc.subject.otherKeywordPlus HISTOPLASMOSIS SYNDROME
dc.subject.otherKeywordPlus PHOTODYNAMIC THERAPY
dc.subject.otherKeywordPlus MULTIFOCAL CHOROIDITIS
dc.subject.otherKeywordPlus LASER PHOTOCOAGULATION
dc.subject.otherKeywordPlus VISUAL PROGNOSIS
dc.subject.otherKeywordPlus EALES-DISEA
dc.subject.otherWOS Ophthalmology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account